featured
2019 Top Stories in Oncology: Inching Closer to Treatment Discontinuation in CLL
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Seymour JF, Ma S, Brander DM, et al. Ventoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase Ib study. Lancet Oncol. 2017;18(2):230-240.
- Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37(30):2722-2739.
- Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095-2103.
Disclosure statements are available on the authors' profiles: